The Biggest IPO Half in History Meets Its H2 Test

The U.S. IPO market just put up its biggest quarter in five years, and the pipeline heading into July suggests the window is still wide open — for now. Renaissance Capital’s Q2 2026 review counts 48 IPOs that raised $104.8 billion in the second quarter, the largest single-quarter total since 2021, led by SpaceX’s record $75 billion listing on June 12.{{cite:chatcmpltool}} Through June 26, Renaissance’s running tally shows 82 IPOs pricing year-to-date for $114.7 billion in proceeds — up roughly 625% from the same period in 2025.{{cite:chatcmpltool}} The question for the second half is whether that pace can hold when two of the deals driving it were one-of-a-kind events, and whether the market can absorb what comes next.

Q2 in Detail: SpaceX and the $1B-Plus Cohort

SpaceX’s June 12 Nasdaq debut under ticker SPCX priced at $135 and closed its first session at $161, a 19% gain — enough to ease concerns about a too-hot or too-cold opening, though the follow-through was bumpier. Across a four-session stretch in late June, SpaceX shed roughly $400 billion in market capitalization, including a single-day decline of about 16%.{{cite:chatcmpltool}} The stock remained above its IPO price, but the volatility underscored that even record demand at issuance does not guarantee clean aftermarket trading.

Even stripping SpaceX out, Q2 was the strongest quarter for IPO proceeds since 2021. Nine other IPOs raised $1 billion or more, led by Cerebras Systems’ $5.55 billion offering on May 13 — the largest AI-chip IPO on record, which opened roughly 89% above its IPO price.{{cite:chatcmpltool}} The ArcStone ECM update identifies the broader thematic lanes: AI infrastructure (Cerebras at $5.55B, Fervo Energy at $1.89B), industrials tied to the AI-power nexus (Forgent Power at $1.5B), and a healthcare cohort that anchored Q1 with seven deals and +43.6% average returns before rotating to negative territory in Q2 as capital migrated toward AI.{{cite:chatcmpltool}}

Source: Renaissance Capital Q2 2026 review; ArcStone ECM Update, June 2026.

The July Calendar: SK hynix Is the Next Stress Test

The week ahead is thin — U.S. markets are closed July 3 for the Independence Day holiday — but the calendar firms up quickly. Two SPACs (Meridian3 Industrials Acquisition at $175M and Viking Acquisition Corp. II at $200M) priced on July 2, and a handful of micro-cap deals (Coolbit Technologies, MetaOptics uplisting, Riku Dining Group, Tarsier Pharma) are scheduled for the week of July 6.{{cite:chatcmpltool}}

The event that matters is July 10: SK hynix’s American depositary receipt listing on Nasdaq under ticker SKHY. The world’s second-largest memory chipmaker plans to raise up to 45.45 trillion won (approximately $29 billion) through new share issuance, with BofA Securities, Citigroup, Goldman Sachs, and J.P. Morgan as lead managers.{{cite:chatcmpltool}} Nikkei Asia reports the offering would rank as the second-largest share flotation in history, behind only SpaceX.{{cite:chatcmpltool}} Proceeds are earmarked for capacity expansion, including construction of the Yongin semiconductor cluster — a direct bet that hyperscaler demand for HBM and DRAM will sustain the capital cycle.{{cite:chatcmpltool}}

What makes SK hynix different from the Q2 cohort is that it is not a venture-backed startup seeking a liquidity event. It is an established, profitable incumbent raising primary capital to fund physical capacity — closer in spirit to Alphabet’s $85 billion follow-on equity raise earlier in 2026 than to a Cerebras or a Lime.{{cite:chatcmpltool}} That means the deal tests a slightly different question: not whether investors want AI exposure (they clearly do), but whether they will absorb a $29B primary issuance from a Korean issuer without demanding a meaningful discount to the parent’s Korea Exchange listing.

The Filing Pipeline: Lime, Kraken, Plaid, and the PE Wave

Behind the priced calendar, the S-1 flow is running at its deepest level since 2021. The most closely watched recent filing is Lime — formally Neutron Holdings — which submitted its registration statement on May 7 and launched its roadshow on June 22 with Goldman Sachs and J.P. Morgan as joint book-runners.{{cite:chatcmpltool}} The S-1 discloses $886 million in revenue across 230 cities and two consecutive years of free cash flow, but also warns that without an IPO, the company faces refinancing risk on looming debt maturities.{{cite:chatcmpltool}} That dual profile — genuine operational progress paired with a financing imperative — is a useful template for several pending deals where the “why now” is not purely opportunistic.

ArcStone identifies Kraken and Plaid as sitting in the Q2/Q3 pipeline, with a combined target of roughly $8 billion.{{cite:chatcmpltool}} JPMorgan flagged in a June note that buyout-backed companies are now the dominant supply source, as private equity firms turn portfolio investments into liquidity events — a structural shift from the venture-backed IPO waves of prior cycles.{{cite:chatcmpltool}} The PE exit dynamic matters because it introduces a different kind of selling pressure: sponsor monetization typically comes with larger float and more aggressive secondary follow-on, not just a one-time primary raise.

Follow-Ons, Convertibles, and Secondaries: Where the Real Volume Lives

The IPO headlines capture attention, but follow-ons and convertibles are doing the heavy lifting on dollar volume. ArcStone reports Q1 follow-on proceeds of $42 billion, with sponsors accounting for an estimated 67% of March volume — vintage 2017–2020 PE funds pressing for LP liquidity.{{cite:chatcmpltool}} Q1 secondary selling reached $20.3 billion, including $13.3 billion in March alone, meaning secondary selling now rivals primary raising in scale.{{cite:chatcmpltool}}

Convertible issuance is running at roughly 2x the 2025 pace, with $34 billion priced through April. Roughly half of that volume is AI-linked, anchored by Oracle’s $5B mandatory convertible preferred and CoreWeave’s $4B deal.{{cite:chatcmpltool}} Issuers are locking in favorable terms while the VIX sits near 16.76 and the 10-year Treasury has pulled back to 4.59% from a 4.92% March peak — conditions that may not persist if the Fed signals a more restrictive posture.{{cite:chatcmpltool}}

Can the Market Absorb It?

The headline risk is that a $200–350B IPO year, plus secondaries that could exceed $400B, will flood the market with supply and force investors to sell existing holdings to make room. UBS pushes back on that framing. In a June 22 note, UBS estimates that gross issuance relative to total U.S. equity market capitalization (~$72 trillion) is only slightly above the long-term average as a percentage of Russell 3000 free float.{{cite:chatcmpltool}} More importantly, U.S. share buybacks totaled $1.2 trillion over the past 12 months and are expected to remain near that level — meaning net equity supply could still shrink even as gross issuance hits records.{{cite:chatcmpltool}} UBS also cites academic literature finding no consistent relationship between IPO activity and forward market returns; the stronger historical pattern is that issuance is a coincident indicator that rises when markets are strong and falls when they weaken.{{cite:chatcmpltool}}

That is the balanced view. The concentration risk is real, though. Two deals — SpaceX and Alphabet — accounted for roughly 68% of the broader H1 issuance tally.{{cite:chatcmpltool}} Strip those out and the remaining market, while healthy, is not at record levels. Average IPO valuations are approximately 10 times their 2022 average,{{cite:chatcmpltool}} which means a single sentiment reset — an AI capex disappointment, a credit event, or a renewed inflation surprise — could re-rate the cohort quickly. Morgan Stanley flagged that Q3 deals are likely to be front-loaded ahead of midterm-election volatility, meaning supply may compress into July and August before thinning out.{{cite:chatcmpltool}}

ArcStone’s scenario framework assigns a 45% probability to the base case — managed volatility, steady tariffs, earnings stay strong, ECM front-loaded into windows — with a 35% bull case and a 20% bear case where an exogenous shock freezes the IPO market as in H1 2022.{{cite:chatcmpltool}}

What to Watch Next

1. SK hynix ADR pricing (July 10). The deal size (~$29B), bookbuild oversubscription level, and first-session premium/discount to the Korea Exchange listing will signal whether global allocators have appetite for a primary capital raise at this scale outside the AI-chip startup narrative.

2. Lime IPO pricing. The roadshow launched June 22; final pricing terms and aftermarket performance will test whether the market rewards a micromobility name with real revenue ($886M) and free cash flow but also visible debt risk — a more nuanced quality test than the pure AI-infrastructure deals that have dominated Q2.

3. S-1 filing pace from PE sponsors. The pace of new registrations from buyout-backed companies will pre-signal whether the H2 calendar can sustain Q2’s volume or whether supply compresses after the front-loaded July window.

4. Renaissance IPO ETF (NYSE: IPO) performance. The cleanest market proxy for newly listed share performance; when broken IPOs spike, sentiment turns and the new-issue window narrows.

5. Convertible issuance tempo. If the VIX drifts higher or the 10-year reverses its retreat, convertible pricing windows tighten quickly. Watch for whether issuers accelerate deals into late July or pull them.

6. Fed signal at the July FOMC meeting. With funds at 3.50–3.75% and the 10-year at 4.59%, any shift in tone toward a more restrictive posture would compress the risk-on backdrop that underpins aggressive issuance pricing.{{cite:chatcmpltool}}